CD19 and cancer: Furthermore, personalized targeted therapies focused on specific genomic alterations that confer resistance to CD19-CAR T cell and BsAb therapies should be considered, and the development of novel therapeutic approaches should pave the way towards a new era of cancer immunotherapy.